Axonics, Inc.
2024
$3.7B
Boston Scientific
Medical DevicesFounded 1979- HQ today: Marlborough, Massachusetts, United States
Reviewed by Swet Parvadiya
Company data updated: November 2026
Acquisitions
Boston Scientific Acquisitions
4
Major Deals Covered
$35.2B
Disclosed Deal Value
What are Boston Scientific's biggest acquisitions?
Boston Scientific's largest disclosed acquisition here is Farapulse, Inc. for $295 in 2021. This page covers 4 major deals from 2006 to 2024, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Farapulse, Inc. ($295)
- First deal
- 2006
- Most recent
- 2024
| Company | Year | Price | Purpose |
|---|---|---|---|
| 2024 | Undisclosed | Sacral neuromodulation systems for urinary and bowel dysfunction, expanding urology portfolio. | |
| 2021 | Undisclosed | Pioneering non-thermal pulsed field ablation system for atrial fibrillation treatment. | |
| 2019 | Undisclosed | Interventional oncology beads, embolization, and targeted vascular therapies. | |
| 2006 | Undisclosed | Cardiac rhythm management, implantable cardioverter-defibrillators, and pacemakers. |
- What companies has Boston Scientific bought?
- Major acquisitions by Boston Scientific documented here include Farapulse, Inc. (2021), Guidant Corporation (2006), BTG plc (2019) and Axonics, Inc. (2024).
- What is Boston Scientific's most recent acquisition?
- The most recent Boston Scientific acquisition documented here is Axonics, Inc., in 2024, for $3.7.
Farapulse, Inc.
2021
$295M
BTG plc
2019
$4.2B
Guidant Corporation
2006
$27.0B
Boston Scientific's Growth & Acquisition Strategy
Under CEO Michael Mahoney, Boston Scientific is executing a clear four-pronged growth strategy: (1) Scaling Global FARAPULSE Adoption: Expanding manufacturing capacity and commercial distribution across North America, Europe, and Asia-Pacific to convert conventional thermal cardiac ablations to pulsed field ablation; (2) Expanding WATCHMAN Indications: Advancing the CHAMPION-AF clinical trial to expand WATCHMAN label indications as a first-line alternative to direct oral anticoagulants (DOACs); (3) Accelerating Endoscopy Single-Use Transition: Commercializing single-use duodenoscopes and bronchoscopes (EXALT platform) to eliminate the risk of hospital patient cross-contamination associated with reprocessed reusable endoscopes; and (4) Expanding Neuromodulation & Pelvic Health via Axonics: Integrating the $3.7B acquisition of Axonics to capture the multi-billion-dollar sacral neuromodulation market for urinary and bowel dysfunction.
How Boston Scientific Makes Money
Boston Scientific operates a high-margin, resilient medical device business model built on single-use consumable catheters, implantable structural devices, and specialized capital equipment: (1) Cardiovascular (~62% of revenue / ~$8.8B), generating robust sales from coronary stents (Synergy), intravascular ultrasound (OptiCross), WATCHMAN left atrial appendage closure devices, and peripheral vascular atherectomy tools; (2) MedSurg (~29% of revenue / ~$4.1B), monetizing disposable endoscopes (Single-Use EXALT), stone management lithotripsy lasers, and urology implants; (3) Neuromodulation (~9% of revenue / ~$1.3B), delivering implantable neurostimulators (WaveWriter Alpha) and deep brain stimulation consoles; and (4) Capital-and-Consumable Placement: Consoles (such as FARASTAR pulsed field ablation generators and POLARx cryoablation consoles) are placed in hospital catheterization labs, locking electrophysiologists into continuous, recurring daily utilization of high-margin single-use catheters. Boston Scientific maintains gross margins above 70% and generates over $2.1 billion in annual free cash flow.
Boston Scientific Acquisitions FAQ
What is Boston Scientific's general approach to M&A and acquisitions?
Boston Scientific pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by Boston Scientific?
Transformative transactions in Boston Scientific's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does Boston Scientific successfully integrate acquired companies?
Boston Scientific deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does Boston Scientific divest non-core corporate assets?
Yes, Boston Scientific periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related Companies
Compare Boston Scientific With Competitors
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Boston Scientific
Core profile pages, founders and related research hubs for this company.